医学临床研究
   Apr. 7, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2022, Vol. 39 Issue (4): 546-549    DOI: 10.3969/j.issn.1671-7171.2022.04.019
Original Articles Current Issue | Archive | Adv Search |
Clinical Effect of Doxorubicin Liposomes in Neoadjuvant Chemotherapy for Stage Ⅱ and Ⅲ Breast Cancer
HAN Qian-qian, HONG Yue-yan, WU Xuan
Oncology Center,The Third Provincial Hospital of Shandong Province,Jinan Shandong 250031,China
Download: PDF (1308 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  【Objective】 To investigate the clinical effect of doxorubicin liposomes in neoadjuvant chemotherapy for stage Ⅱ and Ⅲ breast cancer. 【Methods】Eighty two patients with stage Ⅱ-Ⅲ breast cancer who were admitted to our hospital were recruited in the study. Patients were divided into the observation group and the control group by random method, with 41 cases in each group. The control group received doxorubicin 40 mg/m2 combined with cyclophosphamide 600 mg/m2, sequentially followed by docetaxel 85 mg/m2 neoadjuvant chemotherapy, while the observation group received doxorubicin liposome 40 mg/m2 combined with cyclophosphamide 600 mg/m2 followed by docetaxel 85 mg/m2 chemotherapy for 8 cycles of treatment. The clinical efficacy, surgical treatment and postoperative pathology of the two groups were compared between the two groups. and the incidence of adverse reactions during neoadjuvant chemotherapy were counted. Follow up the survival of the two groups were followed up and performed Kaplan-Meier survival analysis. 【Results】There were no statistically significant differences between the two groups in treatment efficiency, clinical control rate, disease control rate, pathological complete remission rate, and axillary lymph node conversion rate (P>0.05). During the neoadjuvant chemotherapy between the two groups, the incidence of grade Ⅰ~Ⅱ myocardial damage and grade Ⅰ~Ⅱ hand-foot syndrome in the observation group was lower than those in the control group, and the differences were statistically significant (P<0.05). There was no significant difference in the incidence of other side effects between the two groups (P>0.05). Kaplan-Meier survival analysis showed that the 3-year progression-free survival curve of the observation group was better than that of the control group (P<0.05), however, there was no statistically significant difference in the overall survival curve between the two groups (P>0.05). 【Conclusion】The short-term effect of doxorubicin liposome combined with cyclophosphamide sequentially followed by docetaxel neoadjuvant chemotherapy for patients with stage Ⅱ and Ⅲ breast cancer is definitely effective, which can reduce the incidence of myocardial damage and hand-foot syndrome, and prolong progression-free survival, but has no significant effect on overall survival.
Key wordsBreast Neoplasms/DT      Doxorubicin/TU      Antineoplastic Combined Chemotherapy Protocols      Treatment Outcome     
Received: 28 September 2021     
PACS:  R737.9  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
HAN Qian-qian
HONG Yue-yan
WU Xuan
Cite this article:   
HAN Qian-qian,HONG Yue-yan,WU Xuan. Clinical Effect of Doxorubicin Liposomes in Neoadjuvant Chemotherapy for Stage Ⅱ and Ⅲ Breast Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(4): 546-549.
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.04.019     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I4/546
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech